Cancer center communicators—public relations, marketing, and communications experts—are indispensable players in the implementation of the National Cancer Plan, said Peter Garrett, director of NCI’s Office of Communications and Public Liaison.
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
